The Heads of Medicines Agencies, an umbrella group for regulators in 30 European Union countries, plans to launch a “joint action” with the European Commission and the European Medicines Agency to bolster required clinical trial reporting by drug makers and universities.

The move, which emerged from an HMA meeting last week, follows ongoing criticism that too many clinical trial sponsors fail to report study results, an issue that has embroiled drug makers, universities, and policy makers in the U.S. and Europe. The topic has been a flash point following several scandals over safety or efficacy data that were not publicly shared, prompting a greater push for transparency.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]